Expression of major vault protein gene in osteosarcoma patients

Osteosarcoma (OS) is a primary malignant tumor of bone. Despite the successful use of multiple chemotherapeutic agents in the treatment of OS, more than 30% of OS tumors remain resistant to treatment. Elucidation of cellular resistance mechanisms may lead to better treatments for cancer patients. In...

Full description

Saved in:
Bibliographic Details
Published in:Journal of orthopaedic research 2007-07, Vol.25 (7), p.958-963
Main Authors: Dalla-Torre, Cristiane Arruda, de Toledo, Silvia Regina Caminada, Yoshimoto, Maisa, Petrilli, Antônio Sérgio, Andrade, Joyce Anderson Duffles, Chilton-MacNeill, Susan, Squire, Jeremy A., Zielenska, Maria
Format: Article
Language:English
Subjects:
Bone Neoplasms - genetics
Bone Neoplasms - metabolism
Bone Neoplasms - pathology
Child
Child, Preschool
Disease-Free Survival
drug resistance
Drug Resistance, Neoplasm - drug effects
Drug Resistance, Neoplasm - genetics
Female
Gene Expression
Gene Expression Profiling
Humans
Infant
Male
MVP gene
Neoadjuvant Therapy
Oligonucleotide Array Sequence Analysis - methods
osteosarcoma
Osteosarcoma - genetics
Osteosarcoma - metabolism
Osteosarcoma - secondary
Reverse Transcriptase Polymerase Chain Reaction
RNA, Messenger - metabolism
RNA, Neoplasm - analysis
Vault Ribonucleoprotein Particles - genetics
Vault Ribonucleoprotein Particles - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Osteosarcoma (OS) is a primary malignant tumor of bone. Despite the successful use of multiple chemotherapeutic agents in the treatment of OS, more than 30% of OS tumors remain resistant to treatment. Elucidation of cellular resistance mechanisms may lead to better treatments for cancer patients. In this study, we used the low‐density expression cDNA array, GEArray Q Series Human Cancer Drug Resistance and Metabolism Gene Array to screen genes related to drug resistance in 15 OS tumors. Expression patterns of the MPV gene were validated by real time PCR on 45 OS patient tumor samples and correlated with clinical and pathological data. Major vault protein (MVP) expression was present in 24 (53%) tumor samples and absent in 21 (47%). Samples from surgery showed correlation between the expression of MVP, metastatic disease at diagnosis and event free survival (EFS). The MVP gene expression correlates with metastatic disease at diagnosis after neoadjuvant chemotherapy (p = 0.048), and is also associated with worse EFS (p = 0.036). These findings suggest that MVP expression is involved in one of the mechanisms of drug resistance in OS and is induced by chemotherapy. © 2007 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 25:958–963, 2007
ISSN:0736-0266
1554-527X
DOI:10.1002/jor.20371